Back to search

Switzerland· 61263003

Simponi 100 mg, Injektionslösung in einer Fertigspritze

A golimumab product containing golimumabum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L04AB06

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedSimponi 100 mg, Injektionslösung in e…ATCL04AB06REGISTER NO.61263003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Golimumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AB06 (golimumab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Golimumab · ATC L04AB06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
golimumabum
Manufacturer
Janssen-Cilag AG
Country
Switzerland (CH)
ATC code
L04AB06
ATC class
Golimumab
Defined daily dose
1.66 mg, P
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680612630036
    1 ml
    CHF 1446.85

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

429 interactions on record for golimumab.

Graded by severity as the source publishes them — 287 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Golimumab · interactions on record

429 records

  • 287 severe
  • 135 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Golimumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All golimumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Gotenfia
  • Iceland · Gobivaz, Gotenfia
  • Liechtenstein · Gobivaz, Gotenfia
  • Norway · Gobivaz, Gotenfia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a94f3e1d-839c-4565-8b13-0d8c90c8d626
GET /v1/drugs/a94f3e1d-839c-4565-8b13-0d8c90c8d626?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "golimumabum 100 mg",
  "valid_from": "2014-02-01",
  "limitations": "[{\"description\":\"Die Behandlung mit Simponi bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\n<br>\\n<b>Rheumatoide Arthritis:</b> Zur subcutanen Behandlung der aktiven rheumatoiden Arthritis (nur in Kombination mit Methotrexat), wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Psoriasis-Arthritis:</b> Zur subcutanen Behandlung der Psoriasis-Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Morbus Bechterew/ Ankylosierende Spondylitis (AS):</b> Zur Behandlung des Morbus Bechterew/ Ankylosierende Spondylitis, wenn die vorausgegangene konventionelle Therapie unzulänglich war.<br>\\n<br>\\n<b>Moderate bis schwere Colitis ulcerosa:</b> Zur Behandlung erwachsener Patienten mit moderater bis schwerer Colitis ulcerosa, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin oder Glukokortikoiden) unzulänglich war oder nicht vertragen wurde.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-12-01\"}]",
  "galenic_form": "Inj Lös 100 mg/1ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2014-02-01",
  "self_retention_pct": 10
}

See everything about golimumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.